-
1 Comment
Kazia Therapeutics Limited is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kazia Therapeutics Limited's total revenue rose by inf% to $585 since the same quarter in the previous year.
Its net income has dropped by inf% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 348.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Kazia Therapeutics Limited gets an overall score of 2/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for KZIA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
